ActoGeniX Overview
- Year Founded
-
2006
- Status
-
Acquired/Merged
- Employees
-
11
- Latest Deal Type
-
M&A
- Latest Deal Amount
-
$60M
- Investors
-
1
ActoGeniX General Information
Description
Operator of a biopharmaceutical company intended to develop and commercialize a new generation of biological drugs. The company's versatile and proprietary technology platform develops products based on a delivery system comprising living non-pathogenic micro-organisms for the oral administration of biopharmaceuticals, and unmet needs in gastrointestinal, immunological, and metabolic diseases.
Contact Information
Website
www.actogenix.comCorporate Office
- Technologiepark 4
- 9052 Ghent
- Belgium
Corporate Office
- Technologiepark 4
- 9052 Ghent
- Belgium
ActoGeniX Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 8. Merger/Acquisition | 23-Feb-2015 | $60M | Completed | Clinical Trials - General | ||
| 7. Early Stage VC (Series B) | 18-Apr-2013 | Completed | Clinical Trials - General | |||
| 6. Grant | 01-Feb-2011 | Completed | Startup | |||
| 5. Grant | 20-Aug-2009 | Completed | Startup | |||
| 4. Early Stage VC | 24-Mar-2009 | Completed | Startup | |||
| 3. Grant | 01-Jul-2007 | Completed | Startup | |||
| 2. Early Stage VC (Series A) | 06-Feb-2007 | $25.9M | $25.9M | Completed | Startup | |
| 1. University Spin-Out | 01-Jan-2006 | Completed | Startup |
ActoGeniX Patents
ActoGeniX Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| EP-1383897-A2 | Self-containing lactococcus strain | Active | 03-May-2001 | ||
| EP-1383897-B1 | Self-containing lactococcus strain | Inactive | 03-May-2001 | ||
| EP-1194554-A1 | Delivery of trefoil peptides | Active | 05-Jul-1999 | ||
| EP-1194554-B1 | Delivery of trefoil peptides | Inactive | 05-Jul-1999 | C07K14/575 |
ActoGeniX Signals
ActoGeniX Former Investors (9)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Aescap Life Sciences | Mutual Fund | Minority | ||
| Baekeland Fonds II | Corporation | Minority | ||
| Biovest (Belgium) | Venture Capital | Minority | ||
| EQT Life Sciences | Venture Capital | Minority | ||
| Gimv | PE/Buyout | Minority |
ActoGeniX FAQs
-
When was ActoGeniX founded?
ActoGeniX was founded in 2006.
-
Where is ActoGeniX headquartered?
ActoGeniX is headquartered in Ghent, Belgium.
-
What is the size of ActoGeniX?
ActoGeniX has 11 total employees.
-
What industry is ActoGeniX in?
ActoGeniX’s primary industry is Drug Discovery.
-
Is ActoGeniX a private or public company?
ActoGeniX is a Private company.
-
What is the current valuation of ActoGeniX?
The current valuation of ActoGeniX is .
-
What is ActoGeniX’s current revenue?
The current revenue for ActoGeniX is .
-
How much funding has ActoGeniX raised over time?
ActoGeniX has raised $59.8M.
-
Who are ActoGeniX’s investors?
Aescap Life Sciences, Baekeland Fonds II, Biovest (Belgium), EQT Life Sciences, and Gimv are 5 of 9 investors who have invested in ActoGeniX.
-
When was ActoGeniX acquired?
ActoGeniX was acquired on 23-Feb-2015.
-
Who acquired ActoGeniX?
ActoGeniX was acquired by Precigen.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process